LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Orthobond Launches Anti-Microbial Surface Technology
Biologics

Orthobond Launches Anti-Microbial Surface Technology

September 16, 2021 2 min read Premium comments

Advertisement

Secondary#orthobond#antimicrobial#surfacetreatments

It’s hard to get through the first hour of the day without worrying about pathogens these days. Princeton, New Jersey-based Orthobond Corporation, is making a dent in this issue, having just released its patented antimicrobial nano surface technology at the American Academy of Orthopaedic Surgeons annual meeting in San Diego. According to the company, Orthobond’s surface technology is “the only non-eluting and non-antibiotic treatment designed for medical implants.”

Orthobond addresses the contamination issue with an antimicrobial nano surface treatment which kill viruses, bacteria, and fungi by, essentially, rupturing them.

“The world is focused on pathogens more than ever, and we understand the need for protection,” said David Nichols, Orthobond CEO. “Orthobond’s technology creates a covalently bound nano surface that is designed to kill bacteria, viruses and fungi, yet is safe for human contact. Our first products will be a series of antimicrobial medical device surface treatments designed to protect from pathogens without the use of drugs or eluting chemicals, but long term we see broad applications for textiles, consumer goods and high-touch areas in public places.”

Orthobond told OTW that it had tested more than 1,000 different linker-agent combinations to create the ideal solution. “Orthobond’s technology makes use of powerful covalent linker technology that presents a highly efficacious antimicrobial with broad-spectrum activity directly on the device surface.”

Nichols told OTW, “The FIB SEM [focused ion beam scanning electron microscope] images are an amazing means to see the mechanism of action for this surface. We are permanently attaching a 40-nanometer thick surface with our proprietary process creating a density of around 1×1016 molecules per cm2. The surface is not detectable by eye except for a slight color change. The scanning electron microscope images show this surface just ruptures the bacteria on contact like a balloon falling on a bed of sharp pins. I love seeing that activity.”

“Medical device contamination”, explained Nichols, “is the leading cause of failed outcomes. Everything in the operating room is protected from bacteria except the implant. Recent studies show around a 40% rate of contamination on spinal implants aseptically retrieved from patients with poor outcomes.”

“The problem is understood, but the scope was underreported until recent literature. Orthobond has pioneered a non-eluting, non-drug, polycationic nano surface that can be applied to any orthopedic device. The surface shows broad-spectrum efficacy on the most common strains of bacteria seen in orthopedics and will be submitted to the FDA later this year.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy